|
1
|
Vincent MD, Kuruvilla MS, Leighl NB and
Kamel-Reid S: Biomarkers that currently affect clinical practice:
EGFR, ALK, MET, KRAS. Curr Oncol. 19:S33–S44. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Capelletto E and Novello S: Emerging new
agents for the management of patients with non-small cell lung
cancer. Drugs. 72(Suppl 1): 37–52. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Suda K, Mizuuchi H, Maehara Y and
Mitsudomi T: Acquired resistance mechanisms to tyrosine kinase
inhibitors in lung cancer with activating epidermal growth factor
receptor mutation - diversity, ductility, and destiny. Cancer
Metastasis Rev. 31:807–814. 2012. View Article : Google Scholar
|
|
4
|
Liu Y, Shi QF, Ye YC, Tashiro S, Onodera S
and Ikejima T: Activated O2•− and
H2O2 mediated cell survival in
SU11274-treated non-small-cell lung cancer A549 cells via
c-Met-PI3K-Akt and c-Met-Grb2/SOS-Ras-p38 pathways. J Pharmacol
Sci. 119:150–159. 2012.
|
|
5
|
Ayoola A, Barochia A, Belani K and Belani
CP: Primary and acquired resistance to epidermal growth factor
receptor tyrosine kinase inhibitors in non-small cell lung cancer:
an update. Cancer Invest. 30:433–446. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Xu L, Kikuchi E, Xu C, et al: Combined
EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of
lung cancers codriven by mutant EGFR containing T790M and MET.
Cancer Res. 72:3302–3311. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Li D, Ambrogio L, Shimamura T, et al:
BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in
preclinical lung cancer models. Oncogene. 27:4702–4711. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Takezawa K, Okamoto I, Tanizaki J, et al:
Enhanced anticancer effect of the combination of BIBW2992 and
thymidylate synthase-targeted agents in non-small cell lung cancer
with the T790M mutation of epidermal growth factor receptor. Mol
Cancer Ther. 9:1647–1656. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Dulak AM, Gubish CT, Stabile LP, Henry C
and Siegfried JM: HGF-independent potentiation of EGFR action by
c-Met. Oncogene. 30:3625–3635. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Nakachi I, Naoki K, Soejima K, et al: The
combination of multiple receptor tyrosine kinase inhibitor and
mammalian target of rapamycin inhibitor overcomes erlotinib
resistance in lung cancer cell lines through c-Met inhibition. Mol
Cancer Res. 8:1142–1151. 2010. View Article : Google Scholar
|
|
11
|
Liu X, Newton RC and Scherle PA:
Development of c-MET pathway inhibitors. Expert Opin Investig
Drugs. 20:1225–1241. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Nakagawa T, Takeuchi S, Yamada T, et al:
Combined therapy with mutant-selective EGFR inhibitor and Met
kinase inhibitor for overcoming erlotinib resistance in EGFR-mutant
lung cancer. Mol Cancer Ther. 11:2149–2157. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Comoglio PM, Giordano S and Trusolino L:
Drug development of MET inhibitors: targeting oncogene addiction
and expedience. Nat Rev Drug Discov. 7:504–516. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Brambilla E and Gazdar A: Pathogenesis of
lung cancer signalling pathways: roadmap for therapies. Eur Respir
J. 33:1485–1497. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Suda K, Tomizawa K, Osada H, et al:
Conversion from the ‘oncogene addiction’ to ‘drug addiction’ by
intensive inhibition of the EGFR and MET in lung cancer with
activating EGFR mutation. Lung Cancer. 76:292–299. 2012.
|
|
16
|
Branford S, Rudzki Z, Walsh S, et al: High
frequency of point mutations clustered within the adenosine
triphosphate-binding region of BCR/ABL in patients with chronic
myeloid leukemia or Ph-positive acute lymphoblastic leukemia who
develop imatinib (STI571) resistance. Blood. 99:3472–3475. 2002.
View Article : Google Scholar
|
|
17
|
Choi YL, Soda M, Yamashita Y, et al:
EML4-ALK mutations in lung cancer that confer resistance to ALK
inhibitors. N Engl J Med. 363:1734–1739. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wong KK, Fracasso PM, Bukowski RM, et al:
A phase I study with neratinib (HKI-272), an irreversible pan ErbB
receptor tyrosine kinase inhibitor, in patients with solid tumors.
Clin Cancer Res. 15:2552–2558. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Guo A, Villen J, Kornhauser J, et al:
Signaling networks assembled by oncogenic EGFR and c-Met. Proc Natl
Acad Sci USA. 105:692–697. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Engelman JA, Zejnullahu K, Mitsudomi T, et
al: MET amplification leads to gefitinib resistance in lung
cancer by activating ERBB3 signaling. Science. 316:1039–1043. 2007.
View Article : Google Scholar
|
|
21
|
Tang Z, Du R, Jiang S, et al: Dual
MET-EGFR combinatorial inhibition against T790M-EGFR-mediated
erlotinib-resistant lung cancer. Br J Cancer. 99:911–922. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Suda K, Murakami I, Katayama T, et al:
Reciprocal and complementary role of MET amplification and
EGFR T790M mutation in acquired resistance to kinase
inhibitors in lung cancer. Clin Cancer Res. 16:5489–5498.
2010.PubMed/NCBI
|
|
23
|
Bonanno L, Jirillo A and Favaretto A:
Mechanisms of acquired resistance to epidermal growth factor
receptor tyrosine kinase inhibitors and new therapeutic
perspectives in non small cell lung cancer. Curr Drug Targets.
12:922–933. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Bowles DW, Weickhardt A and Jimeno A:
Afatinib for the treatment of patients with EGFR-positive non-small
cell lung cancer. Drugs Today. 49:523–535. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Nelson V, Ziehr J, Agulnik M and Johnson
M: Afatinib: emerging next-generation tyrosine kinase inhibitor for
NSCLC. Onco Targets Ther. 6:135–143. 2013.PubMed/NCBI
|
|
26
|
Chen X, Zhu Q, Zhu L, et al: Clinical
perspective of afatinib in non-small cell lung cancer. Lung Cancer.
81:155–161. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Wang W, Li Q, Takeuchi S, et al: Met
kinase inhibitor E7050 reverses three different mechanisms of
hepatocyte growth factor-induced tyrosine kinase inhibitor
resistance in EGFR mutant lung cancer. Clin Cancer Res.
18:1663–1671. 2012. View Article : Google Scholar
|
|
28
|
Koizumi H, Yamada T, Takeuchi S, et al:
Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs
in EGFR-mutant lung cancer by decreasing client protein expression
and angiogenesis. J Thorac Oncol. 7:1078–1085. 2012. View Article : Google Scholar : PubMed/NCBI
|
